抗TPM4自身抗体与幼年皮肌炎血管病变性皮肤表现的相关性
研究采用Western blotting检测培养的正常人真皮微血管内皮细胞TPM4蛋白表达,并用ELISA检测63例幼年皮肌炎、50例多关节型幼年特发性关节炎和40名健康儿童的血浆抗TPM4自身抗体,发现该抗体在幼年皮肌炎中检出率为30%,且与皮肤溃疡、披肩征皮疹、黏膜病变、皮下水肿及静脉激素和IVIG使用相关。
要点
- 抗TPM4自身抗体在幼年皮肌炎中检出率为30%,多关节型JIA为2%,健康儿童为0%。
- 抗TPM4抗体与皮肤溃疡(53%,P=0.02)、披肩征皮疹(47%,P=0.03)、黏膜病变(84%,P=0.04)、皮下水肿(42%,P<0.05)相关。
- 抗TPM4抗体与静脉激素和IVIG使用显著相关(均P=0.01),且用药总数更多(P=0.02)。
核心结论
- 抗TPM4自身抗体在幼年皮肌炎患儿中频繁检出,是新型肌炎相关自身抗体。
- 其存在与幼年皮肌炎的血管病变性及其他皮肤表现相关,可能提示更难治的疾病。
研究设计与样本
- 研究用Western blotting检测培养的正常人真皮微血管内皮细胞中TPM4蛋白表达。
- 采用ELISA检测63例幼年皮肌炎、50例多关节型幼年特发性关节炎和40名健康儿童血浆中的抗TPM4自身抗体。
- 比较有无抗TPM4自身抗体的幼年皮肌炎患者的临床特征。
主要发现
- 抗TPM4自身抗体在幼年皮肌炎血浆中检出率为30%,多关节型JIA为2%(P<0.0001),健康儿童为0%(P<0.0001)。
- 在幼年皮肌炎中,抗TPM4自身抗体与皮肤溃疡(53%;P=0.02)、披肩征皮疹(47%;P=0.03)、黏膜病变(84%;P=0.04)和皮下水肿(42%;P<0.05)相关。
- 抗TPM4自身抗体与幼年皮肌炎使用静脉激素和IVIG治疗显著相关(均P=0.01)。
- 有抗TPM4自身抗体的患者接受的药物总数更多(P=0.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: AECAs are detected in multiple forms of vasculitis or vasculopathy, including JDM. High levels of tropomyosin alpha-4 chain (TPM4) gene expression in cutaneous lesions and TPM4 protein expression in some endothelial cells (ECs) have been proven. Furthermore, the presence of autoantibodies to tropomyosin proteins have been discovered in DM. We therefore investigated whether anti-TPM4 autoantibodies are an AECA in JDM and are correlated with clinical features of JDM. METHODS: The expression of TPM4 protein in cultured normal human dermal microvascular ECs was investigated by Western blotting. Plasma samples from 63 children with JDM, 50 children with polyarticular JIA (pJIA) and 40 healthy children (HC) were tested for the presence of anti-TPM4 autoantibodies using an ELISA. Clinical features were compared between JDM patients with and without anti-TPM4 autoantibodies. RESULTS: Autoantibodies to TPM4 were detected in the plasma of 30% of JDM, 2% of pJIA (P < 0.0001) and 0% of HC (P < 0.0001). In JDM, anti-TPM4 autoantibodies were associated with the presence of cutaneous ulcers (53%; P = 0.02), shawl sign rash (47%; P = 0.03), mucous membrane lesions (84%; P = 0.04) and subcutaneous edema (42%; P < 0.05). Anti-TPM4 autoantibodies significantly correlated with the use of intravenous steroids and IVIG therapy in JDM (both P = 0.01). The total number of medications received was higher in patients with anti-TPM4 autoantibodies (P = 0.02). CONCLUSION: Anti-TPM4 autoantibodies are detected frequently in children with JDM and are novel myositis-associated autoantibodies. Their presence correlates with vasculopathic and other cutaneous manifestations of JDM that may be indicative of more refractory disease.
引用
- Karasawa R, Yudoh K, Sato T, et al. Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis. Rheumatology (Oxford). 2023. PMID: 37144941. doi:10.1093/rheumatology/kead203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。